Menu
← Oncology Approval Tracker
FDA DECISION ·
Tevimbra
tislelizumab-jsgr · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds 150 mg every two weeks or 300 mg every four weeks with platinum and fluoropyrimidine chemotherapy for adults with previously untreated unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma and tumor PD-L1 expression of at least 1.
LAMPGEN ANALYSIS
Why it matters
The approved alternatives let the checkpoint inhibitor schedule fit different platinum and fluoropyrimidine calendars.
What research teams should watch
Build order sets that distinguish immunotherapy and chemotherapy cycle lengths and document biomarker eligibility.
PRIMARY RECORDS